Politics said to impede EU-Israel trade

Operation Cast Lead’s shadow still hangs over Israeli-European Union trade relations.

June 6, 2012 01:03
2 minute read.
IDF soldiers walk to Gaza in Operation Cast Lead

IDF soldiers walking to Gaza during Operation Cast Lead 311R. (photo credit: Ho New / Reuters)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Operation Cast Lead’s shadow still hangs over Israeli-European Union trade relations more than three years after Israel and Hamas conducted their brief war in the Gaza Strip.

The European Parliament is yet to ratify a 2010 bilateral agreement on mutual acceptance of pharmaceutical products, in the belief that doing so would contravene the EU’s post-Cast Lead policy of not upgrading the 2000 EU-Israel Association Agreement.

Be the first to know - Join our Facebook page.

The European Commission, the body responsible for signing the agreement, is insistent that Parliament approve it as soon as possible, Luigiandrea Pratolongo, head of the EU delegation to Israel’s trade and economics section, told journalists at a seminar in Tel Aviv Tuesday. The delegation hosted the seminar to introduce journalists to the Export Helpdesk, a free online service that helps facilitate market access to the EU.

“We have explained to Parliament that the agreement is part of joint commitments we have in the framework of the [EU-Israel] Action Plan,” Pratolongo said. “We are absolutely convinced that this is not a new element in the relationship with Israel.” The commission would push its case when a parliamentary committee tasked with monitoring such agreements convenes Thursday, he said.

Once approved, the agreement would allow Israeli pharmaceutical companies to export industrial products to the 27 EU member states without requiring European certification, Pratolongo said. Israel is one of only two developed economies (along with South Korea) whose exports receive preferential treatment under free-trade agreements with the EU, he said. European and Israel officials are exploring ways to increase cooperation, despite “the political situation,” he added.

In 2011, the EU was Israel’s main trading partner, with total trade amounting to about 29.5 billion euros, according to the European Commission. EU exports to Israel increased 17 percent to 16.8 billion euros, while imports from Israel grew 14% to 12.6 billion euros. EU exports to Israel consisted mainly of machinery (38.9%), while imports were mainly of chemicals (32.9%), machinery and transport equipment (18.8%) and manufactured goods (16.1%).

Asked whether anti-Israel boycott campaigns had made a negative impact on trade relations, Pratolongo said it was difficult to see from the data because Israeli authorities do not distinguish between products emerging from inside the 1949 cease-fire lines, which are part of the FTA, and products from the West Bank, which do not receive preferential treatment. But trade has been increasing since the bilateral agreement, he said, “so I do not see any impact on the average Israeli producer.”

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection